RecruitingPhase 2NCT04214366

Adenoid Cystic Carcinoma and Carbon Ion Only Irradiation


Sponsor

Heidelberg University

Enrollment

314 participants

Start Date

Dec 1, 2019

Study Type

INTERVENTIONAL

Conditions

Summary

Adenoid cystic tumors are rare tumors of the head and neck region. Despite their slow growth, re-irradiation is often necessary due to the high metastatic risk. Patients are usually irradiated with photons or, as here at the Heidelberg University Hospital, with a combination of carbon ions and photons. So far, there is no data from Europe available for the sole irradiation with carbon ions. The present ACCO (Adenoid Cystic Carcinoma and Carbon ion Only irradiation) study, a prospective, open-label, phase II, single-arm, investigator-initiated study, will therefore investigate the sole radiotherapy of carbon ions in this tumor entity. Irradiation is applied - significantly shorter than the combination therapy - in about 4 weeks (22 fractions); patients are followed up for further 5 years after the start of therapy. Carbon ions alone are expected to increase local tumor control rates from 60% to 70% after 5 years (primary objective criterion of this study). In order to reject the null hypothesis with a power of 80% and a significance level of 5%, 175 patients are included (including a drop-out rate of 15%). Secondary objective criteria are progression-free survival, overall survival, acute and late toxicity, and quality of life.


Eligibility

Min Age: 18 YearsMax Age: 80 Years

Plain Language Summary

Simplified for easier understanding

This study is testing carbon ion radiation therapy alone (without surgery) for patients with adenoid cystic carcinoma (a rare slow-growing cancer) in the head and neck area, to determine whether this specialized type of radiation can control the cancer effectively. **You may be eligible if...** - You have adenoid cystic carcinoma in the head and neck area confirmed by biopsy - Your cancer cannot be removed by surgery, was incompletely removed, or has spread along nerve pathways - You are between 18 and 80 years old - Your general health is adequate (ECOG 0–1 or equivalent) - You have provided informed consent **You may NOT be eligible if...** - Your cancer has spread to distant organs (stage IV with metastases), except for very small lung metastases under 1 cm - Your cancer has spread to lymph nodes - You have previously had radiation to the head and neck area - You have a pacemaker, defibrillator, or other active implant that is not cleared for use with ion radiation - You cannot have an MRI Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

RADIATIONCarbon ion irradiation

22 x 3 Gy(RBE) Carbon Ions

RADIATIONBimodal irradiation

25 x 2 Gy photon IMRT + 8 x 3 Gy(RBE) Carbon ion boost


Locations(1)

University of Heidelberg, Radiooncology, HIT

Heidelberg, Germany

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04214366


Related Trials